Finzati - Logo
TMO logo

Thermo Fisher Scientific Inc.

TMO • Medical - Diagnostics & Research
$687.37
▼ -0.22 (-0.03%)
Current price
EarningsLatest report: Mar 28, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$257.37B
Growth
8.0%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 15.1%Positive free cash flow · 16.74Consistent free cash flow · 5/5Manageable debt level · 0.76Healthy liquidity · 1.89
Financial data as of: Mar 28, 2026, 12:00 AM UTCLast earnings update: Apr 23, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$687.37
Change-0.03%
Shares Out373.00M
Market Cap$257.37B
Enterprise Value$297.27B
52W Range403.36 - 643.99
Beta0.87
P/E37.52
P/S5.69
P/B4.96
P/FCF38.14
EV/Sales6.58

Investment DNA

How strong this company looks for long-term investors

71
out of 100
Business Quality
Margins, moat, returns
76/100
Financial Strength
Debt, cash, stability
82/100
Growth Potential
Revenue and expansion
44/100
Price Attractiveness
Cheap or expensive today
49/100
Why this score▼
Stable or improving margins · 15.1%Positive free cash flow · 16.74Consistent free cash flow · 5/5Manageable debt level · 0.76Healthy liquidity · 1.89

Analyst view

Analyst sentiment and price target

TMO
Analyst sentiment
Based on 43 analyst votes · 2026-10-18
92/100
Bullish
Bullish
36
Hold
7
Bearish
0
Price Target
2026-07-01
Low
$490.00
Mean
$592.45
Median
$615.00
High
$683.00

Company Overview

IPO: 3/17/1980
Industry: Medical - Diagnostics & Research
P/B i: 4.96
Debt / Equity i: 0.76
Operating Margin: 18.20%
Net Margin: 15.12%
ROE i: -
ROIC: -

Financial Health

Score16 / 20
Debt / Equity: 0.76
Current Ratio: 1.89
Quick Ratio: 1.53
Status: Strong

Insider Transactions

Recent executive and insider activity

JOHNSON JENNIFER M
Transaction: 06/27/2026
BUY
Change
—
Price
Not reported
Filing
06/30/2026
Type
BUY
Lynch Karen S
Transaction: 06/27/2026
BUY
Change
—
Price
Not reported
Filing
06/30/2026
Type
BUY
WEISLER DION J
Transaction: 06/27/2026
BUY
Change
—
Price
Not reported
Filing
06/30/2026
Type
BUY